Vanda (VNDA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $20.00 price target.
Ram Selvaraju has given his Buy rating due to a combination of factors including the recent submission of a New Drug Application (NDA) for Bysanti™ (milsaperidone) to the FDA. This drug is intended for the treatment of acute bipolar I disorder and schizophrenia, supported by multiple clinical studies demonstrating its efficacy and safety. If approved, Bysanti could become available in the U.S. by 2026, with potential exclusivity extending into the 2040s, enhancing Vanda’s market position. Additionally, Vanda’s ongoing Phase 3 clinical study for milsaperidone as an adjunctive treatment for major depressive disorder further strengthens its neuropsychiatry portfolio.
Vanda’s strategic initiatives in the neuropsychiatry domain, including the development of a long-acting injectable formulation of Fanapt and the submission of a Marketing Authorization Application to the European Medicines Agency, are expected to drive significant sales growth. The company’s robust balance sheet, with substantial cash reserves and no debt, provides the financial flexibility to pursue additional business development opportunities. These factors, combined with the potential for sustainable profitability by 2026, underpin Selvaraju’s positive outlook and Buy rating for Vanda’s stock.